Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Fokt

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2000
Allosteric, chiral-selective drug binding to DNAX Qu, J O Trent, I Fokt, et al.
Biochemistry|February 20, 1996
Parsing the free energy of anthracycline antibiotic binding to DNAJ B Chaires, S Satyanarayana, D Suh, et al.
Methods in Enzymology|August 10, 2001
Exploiting anthracycline scaffold for designing DNA-targeting agentsW Priebe, I Fokt, T Przewloka, et al.
Journal of Medicinal Chemistry|January 31, 1997
Structure-based design of a new bisintercalating anthracycline antibioticJ B Chaires, F Leng, T Przewloka, et al.
Current Medicinal Chemistry|February 15, 2001
Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug actionA Garnier-Suillerot, C Marbeuf-Gueye, M Salerno, et al.
International Journal of Molecular Sciences|January 8, 2020
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic AgentsB Pajak, E Siwiak, M Sołtyka, et al.
Anticancer Research|March 26, 2002
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activityS Faderl, Z Estrov, H M Kantarjian, et al.
Oncogene|October 18, 2006
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivoA Iwamaru, S Szymanski, E Iwado, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Proceedings of the National Academy of Sciences of the United States of America|October 12, 2000
Allosteric, chiral-selective drug binding to DNAX Qu, J O Trent, I Fokt, et al.
Biochemistry|February 20, 1996
Parsing the free energy of anthracycline antibiotic binding to DNAJ B Chaires, S Satyanarayana, D Suh, et al.
Methods in Enzymology|August 10, 2001
Exploiting anthracycline scaffold for designing DNA-targeting agentsW Priebe, I Fokt, T Przewloka, et al.
Journal of Medicinal Chemistry|January 31, 1997
Structure-based design of a new bisintercalating anthracycline antibioticJ B Chaires, F Leng, T Przewloka, et al.
Current Medicinal Chemistry|February 15, 2001
Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug actionA Garnier-Suillerot, C Marbeuf-Gueye, M Salerno, et al.
International Journal of Molecular Sciences|January 8, 2020
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic AgentsB Pajak, E Siwiak, M Sołtyka, et al.
Anticancer Research|March 26, 2002
WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activityS Faderl, Z Estrov, H M Kantarjian, et al.
Oncogene|October 18, 2006
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivoA Iwamaru, S Szymanski, E Iwado, et al.
Pageof 1